Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
136 hedge funds and large institutions have $415M invested in Merrimack Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
6% more funds holding
Funds holding: 128 → 136 (+8)
5% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 42
28% less capital invested
Capital invested by funds: $574M → $415M (-$159M)
60% less call options, than puts
Call options by funds: $1.17M | Put options by funds: $2.88M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$16.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$14.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.1M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$13.4M |
| 2 |
Millennium Management
New York
|
-$9.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.94M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.62M |
| 5 |
LIM
Lagoda Investment Management
New York
|
-$1.89M |
MACK Hedge Fund Activity: Q4 2016 in Review
136 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2016, worth a combined $415M — down 28% from $574M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MACK positions and 13 closed out — a net gain of 8 holders — while 40 added to existing stakes and 42 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $16.9M. The largest seller was Putnam Investments, cutting an estimated $13.4M.
- 136 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2016, up from 128 in Q3 2016.
- Funds reported $415M of Merrimack Pharmaceuticals, Inc. stock for Q4 2016, down 28% quarter-over-quarter.
- 21 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2016 and 13 closed out, a net change of +8 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2016 was Consonance Capital Management, an estimated $16.9M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2016 was Putnam Investments, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2016.